Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9%) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.

Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey / Franchini, M; Coppola, A; Rocino, A; Zanon, E; Morfini, M; Italian Association of Haemophilia Centers AICE Working, Group; Accorsi, A; Aru, Ab; Biasoli, C; Cantori, I; Castaman, G; Cesaro, S; Ciabatta, C; De Cristofaro, R; Delios, G; Di Minno, G; D'Incà, M; Dragani, A; Ettorre, Cp; Gagliano, F; Gamba, G; Gandini, G; Giordano, P; Giuffrida, G; Gresele, P; Latella, C; Luciani, M; Margaglione, M; Marietta, M; Mazzucconi, Maria Gabriella; Messina, M; Molinari, Ac; Notarangelo, Ld; Oliovecchio, E; Peyvandi, F; Piseddu, G; Rossetti, G; Rossi, V; Santagostino, E; Schiavoni, M; Schinco, P; Serino, Ml; Tagliaferri, A; Testa, S.. - In: HAEMOPHILIA. - ISSN 1351-8216. - STAMPA. - 20:2(2014), pp. 128-135. [10.1111/hae.12334]

Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.

MAZZUCCONI, Maria Gabriella;
2014

Abstract

Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9%) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.
2014
factor concentrates; haemophilia treatment; inhibitor; prophylaxis; survey; viral safety
01 Pubblicazione su rivista::01a Articolo in rivista
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey / Franchini, M; Coppola, A; Rocino, A; Zanon, E; Morfini, M; Italian Association of Haemophilia Centers AICE Working, Group; Accorsi, A; Aru, Ab; Biasoli, C; Cantori, I; Castaman, G; Cesaro, S; Ciabatta, C; De Cristofaro, R; Delios, G; Di Minno, G; D'Incà, M; Dragani, A; Ettorre, Cp; Gagliano, F; Gamba, G; Gandini, G; Giordano, P; Giuffrida, G; Gresele, P; Latella, C; Luciani, M; Margaglione, M; Marietta, M; Mazzucconi, Maria Gabriella; Messina, M; Molinari, Ac; Notarangelo, Ld; Oliovecchio, E; Peyvandi, F; Piseddu, G; Rossetti, G; Rossi, V; Santagostino, E; Schiavoni, M; Schinco, P; Serino, Ml; Tagliaferri, A; Testa, S.. - In: HAEMOPHILIA. - ISSN 1351-8216. - STAMPA. - 20:2(2014), pp. 128-135. [10.1111/hae.12334]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/562762
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact